How U.S. Marijuana Reclassification Could Help Cannabis Companies
Federal cannabis reclassification benefits cannabis companies by reducing regulatory barriers and enabling larger clinical trials. This shift could improve product quality and research funding. It marks a significant step toward evidence-based cannabis…
Explainer: How US Marijuana Reclassification Could Help Cannabis Companies
Marijuana reclassification benefits could reshape the cannabis industry by enabling more rigorous research and easing regulatory burdens. This shift may reduce taxes for cannabis companies and improve product quality. Patients could also gain better…
Marijuana MSOs Surge Amid 2026 Federal Reclassification Report
Marijuana federal reclassification 2026 could remove longstanding research barriers that have limited clinical trials. This shift may accelerate evidence generation for medical cannabis. Clinicians and patients should monitor these changes closely for…
Federal Bill Would Create Cannabis Research Protections – Ganjapreneur
Cannabis research protections are critical to overcoming federal scheduling conflicts that have limited scientific studies. This federal bill aims to reduce regulatory barriers and promote high-quality cannabis research. Improved protections could expand…
The Limits of Averages: A Framework for Contextual Effectiveness in Palliative Care Medicinal Cannabis Research.
This article explores contextual effectiveness in palliative care cannabis research, addressing why patient-reported benefits often differ from clinical trial averages. It highlights the importance of individualized treatment outcomes in medicinal…
Fund a Medical Cannabis Trial for Children Without NHS Access Since 2018
Pediatric medical cannabis trials are urgently needed to improve NHS access for children. Despite legalization in 2018, limited clinical evidence restricts treatment availability. Funding these trials will help establish safety and efficacy data for…
DEA Moves to Allow VA Research Program to Import Marijuana Extract and THC for Clinical Trials
The DEA authorization VA cannabis research marks a pivotal shift enabling clinical trials with standardized marijuana extracts. This federal move supports VA researchers in studying cannabis efficacy for veteran-specific conditions. It promises stronger…
Trump Signs Order to Fast-Track Psychedelic Research | Euronews – CED Clinic
The focus on psychedelic research acceleration aims to speed up evidence generation for psychiatric conditions. This policy shift may influence FDA approval timelines and clinical trial accessibility. It highlights emerging developments in psychedelic…
Joe Rogan Praises Trump’s Executive Order on Psychedelic Research
Psychedelic research funding is crucial for advancing clinical trials and expanding therapeutic options. Trump's executive order aims to accelerate this funding to improve treatment access. This policy shift could significantly impact clinical research…
Medical Cannabis for Orthopaedic Pain: Promising Signal, Weak Evidence Base
Medical cannabis orthopedic pain is a growing area of patient interest despite limited high-quality evidence. This review highlights promising signals for musculoskeletal conditions but notes weak study designs. Clinicians should consider cannabis as…
